Project: Personalized Medicine in Infections: from Systems Biomedicine and Immunometabolism to Precision Diagnosis and Stratification Permitting Individualized Therapies
Acronym | PERMIT (Reference Number: ERAPERMED2018-151) |
Duration | 01/03/2019 - 28/02/2022 |
Project Topic | The PERMIT project proposes to implement personalised medicine in severe infectious diseases, specifically focusing on the rapidly progressing life-threatening necrotizing soft tissue infections (NSTI) as well as the large heterogeneous group of sepsis patients that represent a global health priority. PERMIT builds on the advances and resources created in the FP7-project INFECT, including the world’s largest patient cohort on NSTI, with an associated biobank and multi-omics data (transcriptomics and metabolomics). With this strong foundation, we can advance directly to the phase of preclinical validation of disease signatures/biomarkers and their underlying mechanisms, and the results can be translated into precision diagnosis enabling patient stratification for individualised therapy. One hypothesis to be explored is that immunometabolic processes are dysregulated and contribute to disease and as such, represent targets for tailored therapy. Specific aims are to: 1) identify disease signatures, through dissection of multiomics data, and delineate their underlying mechanisms, 2) engineering of customized organotypic tissue models for validation and intervention studies, 3) validation of identified signatures/biomarkers for patient classification by use of large patient cohorts, 4) development of novel concepts and stratification schemes for adjunctive therapy, 5) exploratory clinical studies of the new trial concepts, 6) data integration and 7) development of rapid decision support tools. Taken together, the activities proposed will demonstrate the clinical feasibility and advantages of personalised medicine in acute infectious diseases. Importantly, the advances are likely to benefit patient outcome through improved diagnostics and therapeutic strategies. To achieve its objective, PERMIT builds on a transnational interdisciplinary consortium of clinicians, experimentalists, bioinformaticians and computational modellers. |
Network | ERA PerMed |
Call | 1st Joint Transnational Call for Proposals (2018) |
Project partner
Number | Name | Role | Country |
---|---|---|---|
1 | Karolinska Institutet | Coordinator | Sweden |
2 | University Hospital of Copenhagen, Rigshospitalet | Partner | Denmark |
3 | Haukeland University Hospital | Partner | Norway |
4 | LifeGlimmer GmbH | Partner | Germany |
5 | Wageningen University | Partner | Netherlands |
6 | Rode Kruis Ziekenhuis (Red Cross Hospital) | Partner | Netherlands |